Q-omics provides the consensus-scored MIR6719 profile across patient tissues and cancer cell-line models. MIR6719 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MIR6719 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MIR6719 RNA expression shows 12,543 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where MIR6719 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6719 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6719 survival associations across molecular data types. MIR6719 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6719 RNA expression–survival associations across cancer types. High MIR6719 expression shows unfavorable associations in KIRC and MESO, but favorable associations in LUAD, UCS, BRCA and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MIR6719 RNA expression.
This table summarizes MIR6719 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6719. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6719 shows higher tumor expression in KIRC, LUSC, LIHC, BLCA, CHOL and COAD. The KIRC box plot shows higher MIR6719 RNA expression in tumor versus normal tissue (log2 FC = +0.520, t-test p < 0.001).
This table shows molecular features associated with MIR6719 in patient tissues and cancer cell lines. In patient samples, MIR6719 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
